Glaucoma management: Relative value and place in therapy of available drug treatments

Therapeutic Advances in Chronic Disease

Volumn 5, Issue 1, 2014, Pages 30-43

  Sambhara, Deepak ^a   Aref, Ahmad A ^b  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Anterior chamber; Glaucoma; Ocular hypertension; Ophthalmic solutions; Optic nerve diseases; Trabecular meshwork; Vision disorders

Indexed keywords

APRACLONIDINE; BETAXOLOL; BIMATOPROST; BIMATOPROST PLUS TIMOLOL; BRIMONIDINE; BRIMONIDINE PLUS BRINZOLAMIDE; BRIMONIDINE PLUS TIMOLOL; BRINZOLAMIDE; CARBACHOL; CARTEOLOL; DEMECARIUM; DIPIVEFRINE; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; ECOTHIOPATE; ECOTHIOPATE IODIDE; GLYCEROL; ISOSORBIDE; LATANOPROST; LATANOPROST PLUS TIMOLOL; LEVOBUNOLOL; MANNITOL; METIPRANOLOL; OCUDOSE; PILOCARPINE; PLACEBO; SANTEN; TAFLUPROST; TIMOLOL; TIMOLOL MALEATE; TIMOLOL PLUS TRAVOPROST; TRAVOPROST; UNCLASSIFIED DRUG; UNOPROSTONE; UNOPROSTONE ISOPROPYL ESTER;

APPLICATION SITE DRYNESS; BLEPHARITIS; BLURRED VISION; CONJUNCTIVAL HYPEREMIA; CONJUNCTIVITIS; CONVULSION; DEHYDRATION; ELECTROCARDIOGRAPHY; ELECTROLYTE DISTURBANCE; EXERCISE; EYE IRRITATION; FATIGUE; GENE THERAPY; GLAUCOMA; HEADACHE; HUMAN; HYPEREMIA; HYPERPIGMENTATION; HYPERTRICHOSIS; HYPOTENSION; INJECTION SITE STINGING; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LIPOATROPHY; META ANALYSIS (TOPIC); METABOLIC ACIDOSIS; NAUSEA AND VOMITING; NEUROPROTECTION; NONHUMAN; OPTIC NERVE DISEASE; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA MACULA EDEMA; REVIEW; SINGLE DRUG DOSE; TACHYCARDIA; TRABECULAR MESHWORK; URINE RETENTION; XEROSTOMIA;

EID: 84898426225     PISSN: 20406223     EISSN: 20406231     Source Type: Journal    
DOI: 10.1177/2040622313511286     Document Type: Review

References (73)

1. AAO (2003) Preferred Practice Patterns in the Management of Glaucoma and Ocular Hypertension. San Francisco, CA: AAO Press.
2. AGIS Investigators (2000) The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 130: 429–440.
3. Aihara M. Oshima H. Araie M. EXTraKT Study Group (2013) Effects of SofZia-preserved travoprost and benzalkonium chloride-preserved latanoprost on the ocular surface - a multicentre randomized single-masked study. Acta Ophthalmol 91 (1): e7–e14.
4. Alm A. Grierson I. Shields M. (2008) Side effects associated with prostaglandin analog therapy. Surv Ophthalmol 53(Suppl. 1): S93–S105.
5. Alqawlaq S. Huzil J. Ivanova M. Foldvari M. (2012) Challenges in neuroprotective nanomedicine development: progress towards noninvasive gene therapy of glaucoma. Nanomedicine (Lond) 7: 1067–1083.
6. Anwar Z. Wellik S. Galor A. (2013). Glaucoma therapy and ocular surface disease: current literature and recommendations. Curr Opin Ophthalmol 24: 136–143.
7. Avorn J. Glynn R. Gurwitz J. Bohn R. Monane M. Everitt D. et al. (1993) Adverse pulmonary effects of topical Beta blockers used in the treatment of glaucoma. J Glaucoma 2: 158–165.
8. Barnebey H. Kwok S. (2000) Patients’ acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting. Clin Ther 22: 1204–1212.
9. Becker B. (1954). Decrease in intraocular pressure in man by a carbonic anhydrase inhibitor, diamox; a preliminary report. Am J Ophthalmol 37: 36–38.
10. Broadway D. Grierson I. O'Brien C. Hitchings R. (1994). Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch Ophthalmol 112: 1446–1454.
11. Butler P. Mannschreck M. Lin S. Hwang I. Alvarado J. (1995) Clinical experience with the long-term use of 1% apraclonidine. Incidence of allergic reactions. Arch Ophthalmol 113: 293–296.
12. Camras C. (1996) Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology 103: 138–147.
13. Camras C. Bito L. (1981). Reduction of intraocular pressure in normal and glaucomatous primate (Aotus trivigratus) eyes by topically applied prostaglandin F 2 alpha. Curr Eye Res 1: 205–209.
14. Cantor L. Liu C. Batoosingh A. Hollander D. (2009) Safety and tolerability of brimonidine purite 0.1% and brimonidine purite 0.15%: a meta-analysis of two phase 3 studies. Curr Med Res Opin 25: 1615–1620.
15. Chang E. Goldberg J. (2012) Glaucoma 2.0: neuroprotection, neuroregeneration, neuroenhancement. Ophthalmology 119: 979–986.
16. Cheng J. Wei R. (2008) Meta-analysis of 13 randomized controlled trials comparing bimatoprost with latanoprost in patients with elevated intraocular pressure. Clin Ther 30: 622–632.
17. Coca-Prados M. Escribano J. (2007) New perspectives in aqueous humor secretion and in glaucoma: the ciliary body as a multifunctional neuroendocrine gland. Prog Retin Eye Res 26: 239–262.
18. Collaborative Normal-Tension Glaucoma Study Group (1998) Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 126: 487–497.
19. Congdon N. Wang F. Tielsch J. (1992) Issues in the epidemiology and population-based screening of primary angle-closure glaucoma. Surv Ophthalmol 36: 411–423.
20. Cucherat M. Stalmans I. Rouland J. (2013) Relative efficacy and safety of preservative-free latanoprost (T2345) for the treatment of open-angle glaucoma and ocular hypertension: and adjusted indirect comparison meta-analysis of randomized clinical trials. J Glaucoma [ePub ahead of print].
21. Demetriades A. (2011) Gene therapy for glaucoma. Curr Opin Ophthalmol 22 (2): 73–77.
22. DuBiner H. Cooke D. Dirks M. Stewart W. VanDenburgh A. Felix C. (2001) Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Surv Ophthalmol 45(Suppl. 4): S353–S360.
23. Filippopoulos T. Paula J. Torun N. Hatton M. Pasquale L. Grosskreutz C. (2008) Periorbital changes associated with topical bimatoprost. Ophthal Plast Reconstr Surg 24: 302–307.
24. Fudemberg S. Batiste C. Katz L. (2008) Efficacy, safety, and current applications of brimonidine. Expert Opin Drug Saf 7: 795–799.
25. Gandolfi S. Simmons S. Sturm R. Chen K. VanDenburgh A. Bimatoprost Study Group 3 (2001) Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther 18: 110–121.
26. Gulati V. Fan S. Zhao M. Maslonka M. Gangahar C. Toris C. (2012) Diurnal and nocturnal variations in aqueous humor dynamics of patients with ocular hypertension undergoing medical therapy. Arch Ophthalmol 130: 677–684.
27. Gupta S. Niranjan D. Agrawal S. Srivastava S. Saxena R. (2008) Recent advances in pharmacotherapy of glaucoma. Indian J Pharmacol 40: 197–208.
28. Halpern D. Pasquale L. (2002) Cystoid macular edema in aphakia and pseudophakia after use of prostaglandin analogs. Semin Ophthalmol 17: 181–186.
29. Heijl A. Leske M. Bengtsson B. Hyman L. Bengtsson B. Hussein M. et al. (2002) Reduction of intraocular pressure and glaucoma progression - Results from the early manifest glaucoma trial. Arch Ophthalmol 120: 1268–1279.
30. Higginbotham E. (1998) Initial treatment for open-angle glaucoma- medical, laser or surgical? Medication is the treatment of choice for chronic open-angle glaucoma. Arch Ophthalmol 116: 239–240.
31. Higginbotham E. (2010) Considerations in glaucoma therapy: fixed combinations versus their component medications. Clin Ophthalmol 4: 1–9.
32. Jampel H. Bacharach J. Sheu W. Wohl L. Solish A. Christie W. et al. (2002) Randomized clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressure. Am J Ophthalmol 134: 863–871.
33. Jayaprakasam A. Ghazi-Nouri S. (2010) Periorbital fat atrophy - an unfamiliar side effect of prostaglandin analogues. Orbit 29: 357–359.
34. Januleviciene I. Derkac I. Grybauskiene L. Paulauskaite R. Gromnickaite R. Kuzmiene L. (2012) Effects of preservative-free tafluprost on tear film osmolarity, tolerability, and intraocular pressure in previously treated patients with open-angle glaucoma. Clin Ophthalmol 6: 103–109.
35. Johnson T. Bull N. Martin K. (2011) Neurotrophic factor delivery as a protective treatment for glaucoma. Exp Eye Res 93: 196–203.
36. Kaiserman I. Fendyur A. Vinker S. (2009) Topical beta blockers in asthmatic patients-is it safe? Curr Eye Res 34: 517–522.
37. Kass M. Heuer D. Higginbotham E. Johnson C. Keltner J. Miller J. et al. (2002) The Ocular Hypertension Treatment Study - A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 120: 701–713.
38. Katz L. (1999) Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group. Am J Ophthalmol 127: 20–26.
39. Katz L. (2002) Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma 11: 119–126.
40. Labbe A. Pauly A. Liang H. Brignole-Baudouin F. Martin C. Warnet J. et al. (2006) Comparison of toxicological profiles of benzalkonium chloride and polyquaternium-1: an experimental study. J Ocul Pharmacol Ther 22: 267–278.
41. Leier C. Baker N. Weber P. (1986) Cardiovascular effects of ophthalmic timolol. Ann Intern Med 104: 197–199.
42. Leske M. (1983) The epidemiology of open-angle glaucoma: a review. Am J Epidemiol 118: 166–191.
43. Lichter P. Musch D. Gillespie B. Guire K. Janz N. Wren P. et al. (2001) Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 108: 1943–1953.
44. Liu J. Kripke D. Weinreb R. (2004) Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure. Am J Ophthalmol 138: 389–395.
45. Liu J. Medeiros F. Slight J. Weinreb R. (2009) Comparing diurnal and nocturnal effects of brinzolamide and timolol on intraocular pressure in patients receiving latanoprost monotherapy. Ophthalmology 116: 449–454.
46. Liu J. Medeiros F. Slight J. Weinreb R. (2010) Diurnal and nocturnal effects of brimonidine monotherapy on intraocular pressure. Ophthalmology 117: 2075–2079.
47. Mizoguchi T. Ozaki M. Unoki K. Dake Y. Eto T. Arai M. (2012) A randomized crossover study comparing tafluprost 0.0015% with travoprost 0.004% in patients with normal-tension glaucoma [corrected]. Clin Ophthalmol 6: 1579–1584.
48. Noecker R. Dirks M. Choplin N. Bernstein P. Batoosingh A. Whitcup S. et al. (2003) A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 135: 55–63.
49. Nordmann J. Mertz B. Yannoulis N. Schwenninger C. Kapik B. Shams N. et al. (2002) A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6 month data. Am J Ophthalmol 133: 1–10.
50. Novack G. O'Donnell M. Molloy D. (2002) New glaucoma medications in the geriatric population: efficacy and safety. J Am Geriatr Soc 50: 956–962.
51. Orzalesi N. Rossetti L. Invernizzi T. Bottoli A. Autelitano A. (2000) Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci 41: 2566–2573.
52. Parrish R. Palmberg P. Sheu W. XLT Study Group (2003) A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 135: 688–703.
53. Quigley H. (1996) Number of people with glaucoma worldwide. Br J Ophthalmol 80: 389–393.
54. Rao V. Epstein D. (2007) Rho GTPase / Rho kinase inhibition as a novel target for the treatment of glaucoma. BioDrugs 21: 167–177.
55. Realini T. (2011). A history of glaucoma pharmacology. Optom Vis Sci 88: 36–38.
56. Sall K. (2000) The efficacy and safety of brinzolamide 1% ophthalmic suspension (Azopt) as a primary therapy in patients with open-angle glaucoma or ocular hypertension. Brinzolamide Primary Therapy Study Group. Surv Ophthalmol 44(Suppl. 2): S155–S162.
57. Sarkar J. Chaudhary S. Namavari A. Ozturk O. Chang J. Yco L. et al. (2012). Corneal neurotoxicity due to topical benzalkonium chloride. Invest Ophthalmol Vis Sci 53: 1792–1802.
58. Schnober D. Hofmann G. Maier H. Scherzer M. Ogundele A. Jasek M. (2010) Diurnal IOP-lowering efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma or ocular hypertension. Clin Ophthalmol 4: 1459–1463.
59. Schuman J. (2000) Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2. Ophthalmology 107: 1171–1177.
60. Sonty S. Mundorf T. Stewart J. Stewart W. (2009) Short-term tolerability of once-daily timolol hemihydrate 0.5%, timolol maleate in sorbate 0.5%, and generic timolol maleate gel-forming solution 0.5% in glaucoma and / or ocular hypertension: a prospective, randomized, double-masked, active-controlled, three-period crossover pilot study. Clin Ther 31: 2063–2071.
61. Stewart R. Kimbrough R. Ward R. (1986) Betaxolol vs timolol. A six-month double-blind comparison. Arch Ophthalmol 104: 46–48.
62. Stewart W. Oehler J. Choplin N. Markoff J. Ichhpujani P. Nelson L. (2013) A comfort survey of timolol hemihydrate 0.5% solution once or twice daily vs timolol maleate in sorbate. J Current Glau Pract 7: 6.
63. Stewart W. Laibovitz R. Horwitz B. Stewart R. Ritch R. Kottler M. (1996) A 90-day study of the efficacy and side effects of 0.25% and 0.5% apraclonidine vs 0.5% timolol. Apraclonidine Primary Therapy Study Group. Arch Ophthalmol 114: 938–942.
64. Tanna A. Rademaker A. Stewart W. Feldman R. (2010) Meta-analysis of the efficacy and safety of alpha2-adrenergic agonists, beta-adrenergic antagonists, and topical carbonic anhydrase inhibitors with prostaglandin analogs. Arch Ophthalmol 128: 825–833.
65. Toris C. Camras C. Yablonski M. (1999) Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am J Ophthalmol 128: 8–14.
66. Toris C. Gabelt B. Kaufman P. (2008) Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol 53(Suppl. 1): S107–S120.
67. Uematsu M. Kumagami T. Shimoda K. Kusano M. Teshima M. Sasaki H. et al. (2010) Influence of alkyl chain length of benzalkonium chloride on acute corneal epithelial toxicity. Cornea 29: 1296–1301.
68. Uusitalo H. Chen E. Pfeiffer N. Brignole-Baudouin F. Kaarniranta K. Leino M. et al. (2010 a) Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol 88: 329–336.
69. Uusitalo H. Pillunat L. Ropo A. Phase III Study Investigators (2010 b) Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study. Acta Ophthalmol 88: 12–19.
70. van der Valk R. Webers C. Schouten J. Zeegers M. Hendrikse F. Prins M. (2005) Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 112: 1177–1185.
71. Wen R. Tao W. Li Y. Sieving P. (2012) CNTF and retina. Prog Retin Eye Res 31: 136–151.
72. Williams R. Novack G. van Haarlem T. Kopczynski C. AR-12286 Phase 2A Study Group (2011) Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension. Am J Ophthalmol 152: 834–841, e831.
73. Woodward D. Chen J. (2007) Fixed-combination and emerging glaucoma therapies. Expert Opin Emerg Drugs 12: 313–327.